Related Experiment Videos
Cardiac valvulopathy associated with pergolide use.
Cindy Zadikoff1, Paula Rochon, Anthony Lang
1Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
Summary
Pergolide therapy for Parkinson's disease is linked to a higher risk of cardiac valvulopathy. However, the exact incidence and clinical significance remain unclear, requiring further investigation.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder.
- Pergolide is a dopamine agonist used in PD treatment.
- Cardiac valvulopathy is a potential adverse effect.
Purpose of the Study:
- To review the risk of pergolide-associated cardiac valvulopathy in Parkinson's disease patients.
- To synthesize current evidence on the incidence and clinical impact of this adverse event.
Main Methods:
- Comprehensive literature search of MEDLINE, Embase, and Cochrane Library.
- Inclusion of all English-language studies and case reports on pergolide and cardiac valvulopathy.
- Data extraction included patient demographics, pergolide dosage/duration, echocardiogram results, and clinical outcomes.
Main Results:
- Twenty-two articles were identified; no randomized controlled trials were found.
- Evidence of valvulopathy was present in all four studies and three case reports analyzing 246 patients.
- Standardized assessment methods for valvular regurgitation were lacking, hindering comparisons; clinical correlation of echocardiogram findings was limited.
Conclusions:
- Pergolide therapy is associated with an increased risk of cardiac valvulopathy.
- The true incidence and clinical importance of this risk are currently unknown.
- Further prospective studies with standardized echocardiogram assessments are necessary.